Hirschsprung's disease (HSCR), a frequent developmental defect of the enteric nervous system is due to lossof-function mutations of RET, a receptor tyrosine kinase essential for the mediation of glial cell-derived neurotrophic factor (GDNF)-induced cell survival. Instead, gain-of-function Cys mutations (e.g., Cys 609 , Cys 620 , and Cys 634 ) of the same gene are responsible for thyroid carcinoma (MEN2A/familial medullary thyroid carcinoma) by causing a covalent Ret dimerization, leading to ligand-independent activation of its tyrosine kinase. In this context, the association of Cys 609 -or Cys 620 -activating mutations with HSCR is still an unresolved paradox. To address this issue, we have compared these two mutants with the Cys 634 Ret variant, which has never been associated with HSCR, for their ability to rescue neuroectodermic cells (SK-N-MC cells) from apoptosis. We show here that despite their constitutively activated kinase, the mere expression of these three mutants does not allow cell rescue. Instead, we demonstrate that like the wild-type Ret, the Cys 634 Ret variant can trigger antiapoptotic pathways only in response to GDNF. In contrast, Cys 609 or Cys 620 mutations, which impair the terminal Ret glycosylation required for its insertion at the plasma membrane, abrogate GDNFinduced cell rescue. Taken together, these data support the idea that sensitivity to GDNF is the mandatory condition, even for constitutively activated Ret mutants, to rescue neuroectodermic cells from apoptosis. These findings may help clarify how a gain-of-function mutation can be associated with a developmental defect.
The RET receptor tyrosine kinase (RTK) provides one of most interesting and documented models of human diseases caused by mutations within a single gene (for a review see reference 37). Its germ line mutations have been associated with Hirschsprung's disease (HSCR), a frequent defect (1 in 5,000 births) of development of the enteric nervous system (ENS) characterized by aganglionosis of the distal digestive tract. RET mutations are also involved in tumor formation: somatic RET chromosomal rearrangements are implicated in papillary thyroid carcinoma, and germ line RET mutations are responsible for the development of three inherited endocrine carcinomas: Familial medullary thyroid carcinoma (FMTC) and multiple endocrine neoplasia types 2A (MEN2A) and 2B (MEN2B).
Detailed biochemical analysis of RET mutations in the MEN2A/FMTC and HSCR families has shown how different mutations can lead to such opposite diseases. Indeed, RET encodes an RTK, expressed in tissues derived from the neural crest such as ENS, thyroid, and adrenal medulla (34, 54) . Its ligand is a complex composed of the survival factor glial-cell line-derived neurotrophic factor (GDNF) (30, 40, 43) and the glycosylphosphatidyl inositol (GPI)-linked protein GFR␣1 (for "GDNF family receptor ␣1") (9, 17, 28, 52) . It has been demonstrated that the GDNF/GFR␣1 binding to Ret elicits its dimerization, which is a prerequisite for the activation of the Ret TK activity and the downstream signaling pathways essential for the survival of enteric crest-derived precursors (51) . Consistently, most HSCR patients are affected by loss-of-function mutations that result in the reduction of Ret expression at the membrane or the abrogation of its intrinsic TK, thereby impairing the transduction of GDNF-induced survival signaling pathways (19, 36, 38) .
Conversely, RET mutations which are responsible for medullary thyroid carcinoma (MEN2A/FMTC) are gain-of-function substitutions that specifically replace one of the six cysteines (Cys 609 , Cys 611 , Cys 618 , Cys 620 , Cys 630 , and Cys 634 ) present in the Ret juxtamembrane domain (15, 32, 33) . Of these cysteines Cys 634 is the most frequently mutated residue in families with MEN2A whereas mutations of Cys 609 , Cys 618 , and Cys 620 are often detected in FMTC (16, 32) . MEN2A and FMTC have the same clinical features, but MEN2A is a more severe syndrome, characterized by the additional occurrence of pheochromocytoma and hyperparathyroidism. Consistently, in vitro experiments conducted with fibroblasts have shown that the Cys 634 substitutions result in a stronger expression, TK activity, and transforming power than the other Cys mutations do (11, 13, 24) . Taken together, these findings have led to the notion that RET loss-of-function mutations cause a developmental defect in the ENS while gain-of-function mutations promote medullary thyroid carcinoma.
Nevertheless, this concept does not fit the puzzling observa-tions that several families presenting HSCR harbor one RET mutation of the MEN2A type at Cys 609 (1) and that patients presenting a double HSCR/MEN2A phenotype carry a unique Cys 618 or Cys 620 mutation (14, 39, 42) . In contrast, the Cys 634 mutations have never been associated with HSCR. This implies that among the activating Cys mutations, some substitutions (Cys 609 , Cys 618 , and Cys 620 ) can lead to impaired development of the ENS. In an attempt to resolve this apparent paradox, it has been proposed that a critical threshold level of Ret activity is necessary to promote neural crest survival (for a review, see reference 49). In this model, the Cys 634 -mutated Ret (Ret 634 ) is believed to be, like the GDNF-stimulated Ret WT , fully activated and thus able to promote cell survival, whereas the lower kinase activity of the Ret 609 or Ret 620 mutants would not be sufficient to reach the threshold level necessary to escape apoptosis (11, 13, 24) . Very little information is currently available about the capacity of these Ret Cys mutants to protect neuroectodermic cells from apoptosis, because most of the studies carried out so far have focused on the capacity of these variants to transform fibroblasts (2, 8, 11, 13, 24, 44) . However, this latter model does not take into consideration the facts that expression of Ret in vivo is restricted to cells of neuroectodermic origin and that enteric crest-derived precursors coexpress Ret and GFR␣1 (58) .
Consistently, we have analyzed the capacity of these different Ret
Cys mutants to promote cell survival using the human neuroectodermic SK-N-MC cell line (55 
MATERIALS AND METHODS
Plasmids. The human cDNA coding for the short isoform of RET (Ret9, 1,072 amino acids) was cloned into the pAlter vector (Promega) and site-directed mutagenesis of Cys 609 3Trp (TGC3TGG), Cys 620 3Arg (TGC3CGC), Cys 634 3 Arg (TGC3CGC), and Met 918 3Thr (ATG3ACG) was performed, as already described (36) . The wild-type (WT) as well as the mutated RET cDNAs were then subcloned into the XbaI site of the pRc/CMV expression vector (In Vitrogen). Mutation of the desired codon was confirmed by complete sequence analysis. The Cys 609 -, Cys 620 -, Cys 634 -, and Met 918 -mutated Ret proteins are referred to throughout this paper as Ret 609 , Ret 620 , Ret 634 , and Ret 2B , respectively. The myc tag was added to the C-terminal end of RET 634 cDNA by PCR. Cell culture, transfections, and treatments. The human neuroectodermic SK-N-MC cell line, which constitutively expresses GFR␣1 but not Ret (55), was cultured in Dulbecco's modified Eagle's medium (Gibco BRL) supplemented with 10% fetal calf serum (Gibco BRL), 2 mM L-glutamine, 100 U of penicillin per ml, and 100 g of streptomycin per ml (referred as complete medium). To generate cell lines expressing either the WT or the mutated Ret, the SK-N-MC cells were stably transfected with 10 g of the corresponding cDNA using the polyethyleneimine (Sigma) precipitation method. At 48 h later, transfected cells were selected in complete medium containing 0.8 mg of G418 (Geneticin; Gibco BRL) per ml. After 2 weeks, at least 100 G418-resistant clones for each mutant were individually picked, expanded, and assayed for Ret expression by anti-Ret Western blotting (C19; Santa Cruz Biotechnology).
Cell treatments. For all experiments, cells were grown to 70% confluency and were serum starved for 6 to 16 h in fresh Dulbecco's modified Eagle's medium supplemented with 0.1% bovine serum albumin (A7030; Sigma) before being subjected to stimulation with GDNF (100 ng/ml; Genentech). When phosphatidylinositol-specific phospholipase C (PI-PLC) (1 U/ml; Oxford Glycosciences) was used to release GPI-linked proteins from the cell surface, it was added to the starvation medium for 90 min. Akt (1:1,000) antibodies (New England Biolabs), as described previously (4) . Ret kinase assay. To determine the effect of the Cys mutations on the RTK activity, the WT and Cys-mutated Ret proteins were immunoprecipitated from cell lysates that were treated previously with GDNF (100 ng/ml) for 15 min or left untreated. Then, their kinase activity was assessed in vitro by measuring their ability to phosphorylate myelin basic protein (MBP; Sigma) (5 g). After a 15-min incubation at 25°C in the presence of [␥-
32 P]ATP (Amersham) (4 Ci), the reaction was stopped by the addition of reduced Laemmli buffer and the products were heated at 100°C for 5 min and resolved by SDS-PAGE (5 to 15% polyacrylamide). The radiolabeled proteins were then transferred to polyvinylidene difluoride membranes and visualized by autoradiography. The intensity of the bands corresponding to phosphorylated MBP was quantified by PhosphorImager (Molecular Dynamics) analysis and was expressed as the fold increase relative to unstimulated Ret WT , which was given the arbitrary value of 1. Immunoprecipitation of equal amounts of Ret was checked by anti-Ret immunoblotting. Control reactions, in which Ret immunoprecipitates were omitted, showed no MBP phosphorylation.
Expression of Ret 634 and GFR␣1 in COS-7 cells. Plates (diameter, 100 mm) of COS-7 cells were transiently transfected with expression plasmids for GFR␣1, a myc-tagged RET 634 , alone or in combination (10 g; ratio 1:10) by the DEAEdextran method, as previously described (4) . Two days after transfection, the cells were depleted for 6 h and treated with GDNF (100 ng/ml) before being subjected to cell lysis with NP-40 buffer supplemented with 1% Brij 96 (Fluka). The myc Ret 634 proteins were then immunoprecipitated with a Sepharose-conjugated anti-myc polyclonal antibody (Clontech).
Endo-H digestion. WCL (50 g) from transfected SK-N-MC cells were denatured at 95°C for 5 min (in a reaction buffer containing 0.2 M sodium citrate [pH 5.5], 0.5% SDS, 1 M ␤-mercaptoethanol, and 0.5% phenylmethyl sulfonyl fluoride) before the addition of Endoglycosidase-H (Boehringer Mannheim). After an overnight incubation at 37°C, the reactions were stopped by the addition of an equal volume of reduced SDS sample buffer (125 mM Tris-HCl [pH 6.8], 10% glycerol, 2% SDS, 5% ␤-mercaptoethanol, 0.01% bromophenol blue) and the reaction products were resolved by SDS-PAGE and analyzed by anti-Ret Western blotting.
Immunofluorescence staining. Cells seeded on a glass coverslip were fixed with methanol for 7 min at Ϫ20°C and permeabilized for 5 min at room temperature with saponin buffer (0.5 % saponin, 2.5% goat serum, 1% bovine serum albumin, and 0.2% gelatin in PBS). Using this saponin buffer throughout the experiment, the cells were incubated overnight with anti-Ret antibodies at 4°C (5 g/ml), washed, and revealed with fluorescein isothiocyanate-conjugated anti-rabbit (Dako) (1:50) antibodies for 1 h at room temperature. Pictures were taken with a 63ϫ magnification lens using a confocal microscope (Leica). The cells incubated with a control rabbit immunoglobulin G showed no staining.
Induction and detection of apoptosis. The indicated cell lines were treated with GDNF or left unstimulated for 1 h before being incubated with the apoptotic agonist anisomycin (10 g/ml) (Sigma). At 3 h later, both adherent (recovered after trypsinization) and nonadherent (present in the culture medium) cells were combined and washed in PBS. Apoptosis was then measured by using flow cytometry (FACScan Becton Dickinson apparatus) to score the percentage of living cells with low transmembrane mitochondrial potential (⌿ M ) among 10,000 gated events (using CellQuest software [Becton Dickinson]). For this purpose, the cells were stained with the mitochondrial fluorochrome 3,3Ј-dihexylocarbocyanine Iodide (DiOC 6 ) (40 ng/ml) (Molecular Probes) for 15 min at 37°C. Propidium iodide (PI) (5 g/ml) (Sigma) was added to stain the dead cells. The cell population with low fluorescence intensity with both DiOC 6 (FL-1) and PI (FL-2) was defined as consisting of the apoptotic cells since compared to the living cells, they display a lower fluorescence intensity with the DIOC 6 probe due to the loss of ⌿ M and they exclude PI (intact membrane).
RESULTS

GDNF increases the tyrosine phosphorylation of Ret 634 in SK-N-MC cells.
We first compared in SK-N-MC cells the signal transduction pathways of Ret 634 mutant with those of the GDNF-stimulated Ret WT . As shown in Fig. 1 , the two types of transfectants expressed comparable levels of the 170-and 150-kDa Ret isoforms, corresponding to the mature cell surface receptor and the intracellular precursor, respectively (56) . We checked by reverse transcriptase PCR that transfection of RET 634 cDNA into SK-N-MC cells did not induce the expression of the endogenous RET WT gene (data not shown). Analysis of anti-Ret precipitates by anti-Ptyr Western blotting indicated that the Ret WT was not phosphorylated in unstimulated cells while addition of GDNF induced a marked increase in its autophosphorylation level (Fig. 1A) . In agreement with previous studies (2, 8, 44) , the p170 isoform of Ret 634 exhibited a constitutive level of activation, as evidenced by its autophosphorylation and the pattern of phosphorylated cellular substrates (Fig. 1B) . However, exposure of SK-Ret 634 cells to GDNF induced a considerable enhancement of Ret 634 autophosphorylation, providing strong evidence that despite its constitutive activation, Ret 634 mutant has retained its sensitivity toward its ligand.
Ret 634 requires GFR␣1 to bind and respond to GDNF. Given that activation of the Ret WT by GDNF depends on the presence of the GPI-anchored protein GFR␣1 (28, 52), we sought to determine whether Ret 634 also needs the expression of GFR␣1 to bind GDNF. To this end, Ret 634 was tagged with a myc epitope at its C terminus and cotransfected with the GFR␣1 cDNA into COS-7 cells. After 48 h, transfected cells were left untreated or incubated with GDNF and lysed. Ret 
FIG. 2. Ret
634 and GFR␣1 form a functional receptor for GDNF. To reconstitute the GFR␣1/Ret 634 complex, the COS-7 cells were transiently transfected with the cDNA of GFR␣1, a myc-tagged RET 634 alone or in combination ("mycRet 634 ϩ GFR␣1," 1:10 ratio). Two days after transfection, the cells were treated with GDNF for 30 min (100 ng/ml) (ϩ) before being subjected to cell lysis with the NP-40 buffer supplemented with 1% Brij 96 to solubilize both Ret 634 and GPIanchored proteins. The mycRet 634 proteins were then immunoprecipitated (Ip) with an anti-myc antibody. The phosphorylation of Ret 634 and the coprecipitation of GFR␣1 and GDNF in the myc immunoprecipitates were detected by anti-Ptyr, anti-GFR␣1, and anti-GDNF Western blotting, respectively. The positions of the p170Ret 634 , GFR␣1 (45 and 60 kDa), and GDNF proteins are indicated by arrowheads. VOL. 21, 2001 MEN2A/HSCR GENOTYPE-PHENOTYPE RELATIONSHIPS 6721
on May 2, 2016 by guest http://mcb.asm.org/ teraction of GDNF with Ret 634 was not direct but occurred through GFR␣1. Accordingly, GDNF stimulation resulted in the coprecipitation of GFR␣1 with Ret 634 . These results demonstrate that the concomitant presence of Ret 634 , GFR␣1 and GDNF was necessary to stabilize the complex. Consistently, the ability of GDNF to increase Ret 634 autophosphorylation, as revealed by anti-Ptyr Western blotting, was observed only when cells coexpressed GFR␣1. These results provide the first evidence that, similarly to the WT form (28, 52) , Ret 634 can bind and respond to GDNF, provided that GFR␣1 is coexpressed.
The activated Ret 634 mutant needs to bind the GDNF/ GFR␣1 complex to rescue SK-N-MC cells from apoptosis. Given the critical role played by GDNF in promoting neuroectodermic cell survival via the activation of Ret TK (51), we were interested in determining whether GDNF was still required for the survival of neuroectodermic cells expressing the constitutively activated Ret 634 mutant. To investigate this, we treated, the SK-Ret WT and SK-Ret 634 cells with GDNF or left then unstimulated for 1 h and then incubated them for 3 h with the apoptotic agonist anisomycin. Apoptosis was then assessed by scoring the percentage of living cells exhibiting a collapsed mitochondria potential (⌿ M ), after DiOC 6 staining. As shown in Fig. 3A , GDNF preincubation protected the SK-Ret WT cells from anisomycin-induced apoptosis whereas the sole expression of the Ret 634 mutant failed to rescue SK-N-MC cells from apoptosis, despite its constitutive activation. In accordance with the above-demonstrated ability of Ret 634 to bind and respond to GDNF, SK-Ret 634 cells were rescued from anisomycin-induced apoptosis by GDNF. This prompted us to investigate whether Ret 634 could activate Akt and extracellular signal-regulated kinase (ERK), two serine/threonine kinases that are involved in cell survival (for a review, see reference 26). As shown in Fig. 3B , the Ret 634 mutant was not or barely constitutively coupled to these pathways, while addition of GDNF induced the activation of both ERK and Akt in SKRet WT as well as in SK-Ret 634 cells. To ensure that GDNF needs to bind to GFR␣1 to mediate its antiapoptotic effect, SK-Ret 634 cells were pretreated with phosphatidylinositide-specific phospholipase C (PI-PLC) to remove GPI-linked proteins from the cell membrane. As shown in Fig. 4 , this treatment markedly diminished concomitantly GDNF-induced Ret 634 autophosphorylation (Fig. 4A ) and Akt and ERK activation (Fig. 4B) and abrogated the rescuing effect of GDNF on anisomycin-treated SK-Ret 634 cells (Fig. 4C) . Importantly, addition of soluble GFR␣1 (sGFR␣1) in combination with GDNF restored all these responses, indicating that, as established for Ret WT (28, 52) , Ret 634 did have to form a ternary complex with GFR␣1 and GDNF to mediate the antiapoptotic signaling pathways.
GDNF does not protect SK-Ret 609 and SK-Ret 620 cells from apoptosis. Germ line RET mutations at Cys 609 or Cys 620 were found in several families who develop HSCR in addition to MEN2A/FMTC (14, 31, 42) . In an attempt to explore the molecular defects engendered by this type of mutation, Cys 609 3Trp or Cys 620 3Arg mutated RET cDNA was transfected into SK-N-MC cells. As shown in Fig. 5 , the Ret 609 and Ret 620 mutants exhibited an autophosphorylation level (Fig. 5A) and an in vitro kinase activity (Fig. 5B ) significantly higher than those of the unstimulated Ret WT . However, at variance with Cys 634 mutation, these two mutants were weakly activated and were expressed mainly in a p150 form instead of the normal p170/p150 doublet (Fig. 5A) , confirming previous results obtained with fibroblasts and PC12 cells (11, 13, 24, 38) . Indirect immunofluorescence in SK-N-MC cells has allowed us to localize the p150 Ret precursor in the reticulum and the p170
Ret receptor at the plasma membrane (56) . To ascertain that the p150 forms of Ret 609 and Ret 620 corresponded to the immature form and not to a proteolytic fragment of p170
Ret , cell lysates were treated with Endo-H and the products were analyzed by anti-Ret Western blotting. Endo-H can digest the N-linked immature oligosaccharides of the precursor before they are processed in the Golgi apparatus. As shown in Fig. 5C , Endo-H completely digested the p150 forms of Ret 609 and Ret 620 into a 120-kDa band that comigrated with the digested product of the p150 form of Ret 634 , strongly suggesting that the p150 forms of Ret 609 , Ret 620 and Ret 634 indeed corresponded to the same intracellular precursor. At that stage, it was of interest to address whether these different Ret Cys mutants presented the same subcellular localization. To this end, the cells were fixed and permeabilized before being stained with anti-Ret antibodies and ultimately analyzed by confocal microscopy. As shown in Fig. 5D , both the Ret WT and Ret 634 mutants preferentially exhibited a cell surface localization whereas we failed to detect any trace of membrane staining on SK-Ret 609 and SK-Ret 620 cells. Instead, these latter variants localized in a perinuclear zone, probably corresponding to the endoplasmic reticulum.
We therefore investigated the consequences of the expression of Ret 609 and Ret 620 mutants on the survival of neuroectodermic cells. We found that the simple expression of Ret 609 and Ret 620 did not induce SK-N-MC cell death (Fig. 6B ) or protect these cells from apoptosis, strengthening the idea that these constitutively activated Ret Cys mutants were unable to trigger antiapoptotic signaling pathways. Furthermore, addition of GDNF to SK-Ret 609 or to SK-Ret 620 cells failed to enhance the phosphorylation level (Fig. 5A ) and the kinase activity (Fig. 5B ) of these two Ret variants, nor did it induce the activation of Akt and ERK (Fig. 6A) , in contrast to what we observed in SK-Ret 634 cells (Fig. 5 and 6 ). Consistently, GDNF did not protect the SK-Ret 609 or SK-Ret 620 cells from anisomycin-induced apoptosis (Fig. 6B) . These data strongly suggest that the intracellular retention of Ret 609 and Ret 620 prevented these mutated forms from interacting with the GDNF/GFR␣1 complex, thus precluding the activation of the antiapoptotic pathways.
Activation of the PI3K/Akt pathway correlates with the ability of the MEN2B Ret mutant to rescue SK-N-MC cells from apoptosis. The Met
918 3Thr substitution within the Ret TK domain is responsible for MEN2B, an inherited cancer syndrome defined, like MEN2A, by the presence of medullary thyroid carcinoma and pheochromocytoma (12, 22) . However, in the ENS, MEN2B differs from MEN2A by the development of ganglioneuroma. It is therefore of interest to investigate the possibility that Met 918 -mutated Ret (referred as Ret 2B ) triggered both the activation of Akt and ERK and cell rescue in SK-N-MC cells. As shown in Fig. 7 , the Ret 2B mutant was expressed under the p170
Ret and p150 Ret isoforms. The high autophosphorylation level of p150
Ret2B revealed the constitutive activation of Ret 2B that, in turn, elicited the phosphorylation of several cellular substrates. Nonetheless, Ret 2B , which was shown by confocal microscopy (Fig. 7B) to be expressed at the plasma membrane, retained its sensitivity toward GDNF since GDNF significantly enhanced the autophosphorylation level of the p170
Ret2B form. However, in contrast to Ret 634 , Ret 2B was able by itself to constitutively activate Akt bur not ERK, whose activation was strictly dependent on the presence of GDNF (Fig. 8A ). In agreement with what is known about the upstream regulation of Akt, p85 PI3K was constitutively recruited by Ret 2B along with several phosphorylated proteins of 46, 52 and 120 kDa (Fig. 8B) . This is in accord with recent data showing the assembly of a multimolecular complex including Ret, p46
Shc , p52 Shc , p120 Gab , and p85 PI3K (3, 21) . Conversely, coprecipitation of p85 PI3K with either Ret WT -or Ret 634 -containing complex did require ligation to GDNF. Interestingly, one should notice that the mere expression of Ret 2B allowed cell rescue in the absence of GDNF. Exposure to GDNF did not further protect SK-Ret 2B cells to anisomycin-induced apoptosis. Taken together, these findings reinforce the idea that the PI3K/Akt pathway is the key step that must be activated by Ret mutant to protect the cell from apoptosis.
DISCUSSION
Throughout development and life, the Ret RTK is essential for the mediation of the GDNF survival signals. Like all RTK, Ret exists as an inactive monomer until it binds its ligand, which drives its dimerization, required for the activation of its intrinsic TK activity. Consistently, RET gain-of-function mutations are involved in tumor formation while loss-of-function mutations are associated with developmental defects (37) . Among the activating mutations, much effort has been devoted VOL. 21, 2001 MEN2A/HSCR GENOTYPE-PHENOTYPE RELATIONSHIPS 6725
on May 2, 2016 by guest http://mcb.asm.org/ to delineating how Cys substitutions could result in Ret activation and thereby in the transformation of fibroblasts. It turned out that these mutations result in the dimerization of the mutated Ret via the formation of an intermolecular disulfide bond and hence in the permanent activation of its intrinsic TK (2, 8, 44) . Based on these features, the Cys mutants seem locked in a dimeric activated state that mimics the ligandoccupied receptor. This has led to the notion that these mutants are ligand-insensitive oncogenes that support by themselves cell transformation but also, by inference, support all the ligand-induced effects. Intriguingly, several families with ENS defect (HSCR) harbor one RET gain-of-function mutation at (41, 49) . To address this issue, we have compared the consequences of these substitutions in terms of cell survival with those of the Cys 634 mutation, which has never been associated with HSCR.
The explanation proposed for the normal development of the RET 634 -carrying patients is that Ret 634 shares with GDNFstimulated Ret WT the capacity for promoting the signaling required for neuroectodermic cell survival (for a review, see reference 49), but this hypothesis still lacks experimental support. To this end, the RET WT or the RET 634 cDNA was transfected into the neuroectodermic SK-N-MC cell line, which constitutively expresses GFR␣1 (55) . We found that GDNF stimulation of Ret WT in this cellular model induced phosphorylation of several cellular substrates, activation of the ERK and Akt pathways, and protection of SK-N-MC cells from anisomycin-induced apoptosis. We then confirmed that the mere expression of Ret 634 resulted in phosphorylation of the same substrates as those lying downstream of the GDNFstimulated Ret WT . However, this mutant failed to activate ERK and Akt and to protect these cells from apoptosis. These data indicate that even though the constitutive activity of Ret 634 mutant is sufficient for fibroblast transformation (2, 8, 24, 44) , it was not able to protect neuroectodermic cells from apoptosis. This is in apparent contrast to a recent report showing that Ret 634 constitutively activates the PI3K/Akt pathway in fibroblasts (47) . An attractive hypothesis to explain this discrepancy might be to consider that the signaling generated by the Ret 634 mutant depends critically on the cell type, as previously reported (57 and GFR␣1 (10) , supporting the idea that the oncogenic power of Ret 634 is independent of GDNF. This prompted us to investigate whether GDNF might trigger survival signaling pathways in neuroectodermic Ret 634 -expressing cells. We demonstrated that exposure of SK-Ret 634 cells to GDNF produced a dramatic enhancement of Ret 634 autophosphorylation, the subsequent induction of ERK and Akt activities, and a concomitant protection of SK-Ret 634 cells from apoptosis. We found that all these GDNF-dependent events required the coexpression of GFR␣1. Consistently, Ret 634 retained its capacity to form a ternary complex with GDNF and GFR␣1. In this regard, it is of interest that in PI-PLC-treated SK-Ret 634 cells, addition of soluble GFR␣1 allowed GDNF to exert its protective effect. However, it was less efficient in activating Akt, consistent with the notion of an Akt threshold requirement. This strongly suggests that the recruitment of Ret 634 to lipid raft via the GPI-anchored protein GFR␣1 is an important step for the full activation by GDNF of Ret 634 signaling, as recently demonstrated for the Ret WT (50) . These findings point to the important notions that activation of Ret 634 by GDNF is absolutely required for neuroectodermic cell survival and that the signaling pathways induced by GDNF in the SK-Ret 634 cells are indistinguishable from those induced in the Ret WT -expressing cells.
In the RET 609 -or RET 620 -carrying patients, ENS development can be severely impaired (1, 14, 31, 42) . In an attempt to explain these puzzling observations, it has been proposed that the Ret 609 and Ret 620 mutants display a TK activity under the threshold required to promote neuroectodermic cell survival (49) . Alternatively, it has been assumed that these two mutants trigger a signaling pathway that commits the cell to death (37, 46) . We found that when expressed in SK-N-MC cells, the Ret 609 and Ret 620 variants exhibited a constitutive TK activity higher that those of the Ret WT . However, at variance with Cys 634 mutations, these two mutations were weakly activating. In contrast to the above-mentioned hypotheses, the expression of Ret 609 and Ret 620 did not by itself cause the death of SK-N-MC cells. Furthermore, addition of GDNF did not increase Ret 609 and Ret 620 phosphorylation levels or induce the activation of Akt and ERK. Consistently, GDNF could not protect the SK-Ret 609 nor the SK-Ret 620 cells from anisomycin-induced apoptosis. This was correlated with the intracellular accumulation of these mutants under a 150-kDa incompletely glycosylated form. In this regard, evidence of retention of misfolded and incompletely glycosylated Ret molecules in the endoplasmic reticulum (6, 13) is of particular interest, suggesting that a blockade in the glycosylation process of Ret 609 and Ret 620 mutants prevents their insertion into the plasma membrane.
Taken together, these data demonstrate that the activated 
Ret
Cys mutants do not function as originally expected: none of the three Ret Cys variants was able per se to rescue neuroectodermic cells from apoptosis. Only the GDNF binding to Ret WT and Ret 634 was capable of generating antiapoptotic pathways. Indeed, we could demonstrate that the inability of the Ret Cys mutants to trigger these antiapoptotic pathways was independent of their level of expression (data not shown), their subcellular localization, and their extent of activated state. In fact, Ret 634 , which was expressed at the cell surface and displayed a TK activity twice that of GDNF-stimulated Ret WT , was unable to ensure a survival signaling. These findings definitively invalidate the "threshold" model and, rather, support a model in which the Ret 634 mutant is not only sensitive to but also entirely dependent on its ligation to GDNF for triggering neuroectodermic cell survival. This implies that ligand binding is able to activate signals that are qualitatively different from that resulting from the covalent dimerization imposed by the Cys mutations. In support of this hypothesis, recent studies have evidenced that the unliganded receptor can adopt inactive dimeric conformations that are different from those of the activated receptor complexed with ligand (for a review, see reference 27). This poses the question of what "activating mutation" means. To address this issue, we have studied the consequences on cell survival of the Met 918 3Thr RET substitution (Ret 2B ), another gain-of-function mutation responsible for MEN2B that has never been associated with HSCR. This substitution leads to Ret activation by forcing its catalytic domain into a constitutively activated conformation (8, 12, 22, 44) . When expressed in SK-N-MC cells, Ret 2B was constitutively activated, was expressed at the cell surface, and retained its sensitivity towards GDNF. However, in the absence of GDNF, Ret 2B could at the same time induce cell rescue and activation of the PI3K/Akt pathway. This is in contrast to what we observed for the Ret 2B -mediated activation of ERK, which still necessitated GDNF. Constitutive activation of the PI3K/Akt pathway may be in relation to the reported changes in Ret 2B autophosphorylation sites (25, 29) and substrate specificity (4, 35, 45, 48) , compared to Ret WT , and Ret 634 . This is a fundamental point that distinguishes Ret 2B from Ret 634 in neuroectodermic cells and may underlie the differences in the phenotypes of patients carrying these respective germ line mutations. Indeed, MEN2B is defined, as is MEN2A, by the occurrence of medullary thyroid carcinoma and pheochromocytoma. However, MEN2B displays a more complex and severe phenotype characterized by rapid disease progression and interestingly, ganglioneuromas in the intestinal tract. Concerning the Ret 609 and Ret 620 mutants, our data support the idea that these variants failed to ensure cell survival because their intracellular location impede their interaction with the membrane-associated GDNF/GFR␣1 complex. These observations may help clarify why the RET 609 -and RET 620 -carrying patients have impaired ENS development. The fact that the HSCR phenotype is present in only a small number of families with recurrence of FMTC and in few carriers within these families has to be ascribed to the intrinsic complexity of the HSRC etiology. Indeed, compelling studies indicate that the expression of the HSRC phenotype does not arise solely from the presence of a mutation but, rather, involves the contribution of converging components such as the genetic background and the action of environmental factors or modifying genes (5, 7, 18, 20, 23 ). An exciting challenge for future studies would be to characterize these factors and to verify whether the completion of the glycosylation process of Ret 609 and Ret 620 mutants could restore their expression at the cell surface and hence their sensitivity to GDNF.
